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Abstract: Förster resonance energy transfer (FRET) -based techniques have recently been 
applied to study the interactions between β-site APP-cleaving enzyme-GFP (BACE1-GFP) 
and amyloid precursor protein-mRFP (APP-mRFP) in U373 glioblastoma cells. In this 
context, the role of APP-BACE1 proximity in Alzheimer’s disease (AD) pathogenesis  
has been discussed. FRET was found to depend on intracellular cholesterol levels and 
associated alterations in membrane stiffness. Here, NPC1 null cells (CHO-NPC1−/−), 
exhibiting increased cholesterol levels and disturbed cholesterol transport similar to that 
observed in Niemann-Pick type C disease (NPC), were used to analyze the influence of 
altered cholesterol levels on APP-BACE1 proximity. Fluorescence lifetime measurements 
of whole CHO-wild type (WT) and CHO-NPC1−/− cells (EPI-illumination microscopy), as 
well as their plasma membranes (total internal reflection fluorescence microscopy, 
TIRFM), were performed. Additionally, generalized polarization (GP) measurements of 
CHO-WT and CHO-NPC1−/− cells incubated with the fluorescence marker laurdan were 
performed to determine membrane stiffness of plasma- and intracellular-membranes.  
CHO-NPC1−/− cells showed higher membrane stiffness at intracellular- but not  
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plasma-membranes, equivalent to cholesterol accumulation in late endosomes/lysosomes. 
Along with higher membrane stiffness, the FRET efficiency between BACE1-GFP and  
APP-mRFP was reduced at intracellular membranes, but not within the plasma membrane 
of CHO-NPC1−/−. Our data show that FRET combined with TIRF is a powerful technique 
to determine protein proximity and membrane fluidity in cellular models of 
neurodegenerative diseases. 




Brain cholesterol is the main component of cellular membranes in the central nervous system 
(CNS) and plays an essential role in regulation of membrane fluidity, and thereby, structural integrity 
and functional specificity at various cellular locations is important for neuronal development and 
survival [1–4], synapse maturation and optimal synaptic activity [5,6]. As a consequence, brain 
cholesterol homeostasis is essential for the physiological function of the CNS, and imbalanced brain 
cholesterol levels are linked to neurodegenerative diseases including Huntington’s disease (HD) [7,8], 
Parkinson’s disease (PD) [9–11], Alzheimer’s disease (AD) [12–15] and Niemann–Pick type C disease 
(NPC) [16–18].  
The amyloid hypothesis of AD pathogenesis favors amyloid-β peptide (Aβ), a product of the 
sequential proteolytic cleavage of the transmembrane amyloid protein precursor (APP) by β-site  
APP-cleaving enzyme (β-secretase or BACE1) and γ-secretase, as a trigger for AD [19–22]. The 
proteolytic processing of APP by β- and γ-secretase occurs predominantly in cholesterol-rich 
microdomains, so called lipid rafts, at intracellular membranes [23–27]. Several risk factors for AD are 
associated with cholesterol metabolism, including dyslipidaemia, coronary artery and cerebrovascular 
disease [28]. Apart from age, the ε4 allele of Apolipoprotein E (ApoE), a cholesterol carrier, is the 
major risk factor for sporadic AD [29–32]. Several independent studies have shown that changes in 
cholesterol level lead to altered APP processing by BACE1 and, subsequently, altered levels of APP 
fragments (Aβ and secreted APPβ (sAPPβ)) [27,33–35]. Niemann–Pick type C disease (NPC) is a 
lysosomal storage disorder caused by mutations in the genes NPC1 or NPC2. The resulting 
dysfunction in proteins involved in intracellular cholesterol transport and homeostasis leads to 
intracellular accumulation of cholesterol and sphingolipids in late endosomes and lysosomes [18,36,37]. 
NPC symptoms include progressive ataxia, dystonia and dementia. An increasing number of studies in 
cell culture, as well as in animal models, revealed parallels in the molecular mechanisms of NPC and 
AD pathology [38–41]. Like AD, NPC goes along with impaired cholesterol homeostasis, altered APP 
metabolism and abnormal tau phosphorylation [42].  
In previous experiments, we and others demonstrated that APP processing by BACE1, and 
subsequently sAPPβ secretion, is increased with rising intracellular cholesterol levels, whereas sAPPα 
secretion is reduced [33]. Cholesterol depletion by MβCD leads to the opposite effect [33–35,43,44]. 
Using EPI-illumination microscopy (for detection of whole cells) combined with FRET measurements, 
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we have recently shown [33] that APP-mRFP and BACE1-GFP proximity was decreased at 
intracellular compartments associated with increased cholesterol level and membrane stiffness, 
whereas no changes could be observed at the plasma membrane, as measured by FRET experiments 
under TIRFM conditions (further abbreviated as TIRET). Increased APP cleavage by BACE1 and 
sAPPβ secretion was likewise found in CHO-NPC1−/− cells [35]. As these cells are also enriched in 
intracellular cholesterol, we used them to extend our previous study regarding membrane stiffness and 
altered proximity of APP and BACE1 upon increased cholesterol levels.  
2. Results and Discussion 
2.1. CHO-NPC1−/− Cells are Enriched in Total, as well as, Vesicular Cholesterol 
As we wanted to compare the measurements with our recently published data of cholesterol loaded 
and depleted glioblastoma astrocytoma U373 cells [33], we first performed cholesterol level 
measurements of CHO-WT and CHO-NPC1−/− cells (Figure 1). As expected, CHO-NPC1−/− cells had 
a significantly higher free and total cholesterol levels compared to CHO-WT. To further visualize the 
distribution of free cholesterol within the cells, we performed filipin staining (Sigma-Aldrich). As 
described for NPC, we found highly increased vesicular distribution of free cholesterol in  
CHO-NPC1−/− cells compared to CHO-WT (Figure 1). 
Figure 1. CHO-NPC1−/− cells show increased levels of free and total cholesterol and 
vesicular accumulation of free cholesterol. Cholesterol levels (total cholesterol, free 
cholesterol and cholesterol esters) and free cholesterol accumulation were analyzed in 
CHO-NPC1−/− vs. CHO-WT cells. Cholesterol levels were determined in cell lysates by 
AmplexRed Cholesterol Assay (Invitrogen, Darmstadt, Germany) (left panel). Note that 
total cholesterol in CHO-NPC1−/− cells is mainly comprised of free cholesterol, with only 
negligible amounts of esterified cholesterol. Shown are the mean and SEM of three 
independent experiments. Statistical analysis was performed using Student’s t-test:  
** p < 0.01. Filipin staining shows punctuate accumulation of free cholesterol in  
CHO-NPC1−/− cells compared to CHO-WT cells (right panel). 
 
Interestingly, we found that CHO-NPC1−/− cells had a cholesterol level comparable with 
cholesterol depleted U373 glioblastoma cells (Supplementary Table S1). This can be explained by the 
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high cholesterol levels in astrocytes. Astrocytes supply neurons with cholesterol, as neurons do not 
produce enough cholesterol on their own.  
2.2. NPC1−/− Cells Display Higher Membrane Stiffness at Intracellular Membranes 
To further analyze differences in membrane stiffness associated with altered cholesterol levels, we 
used the previously described method of wide-field fluorescence microscopy for measuring membrane 
dynamics of living cells based on 6-dodecanoyl-2-dimethylamino naphthalene (laurdan) staining and 
generalized polarization (GP) measurements [45]. As reported previously [45,46], GP represents a 
normalized value for the difference of fluorescence intensity in two spectral bands, with the first one 
being predominant in a rather stiff-, and the second one in a more fluid environment. Using TIRF and 
EPI-illumination, we were able to distinguish between alterations of membrane stiffness at the plasma 
membrane and intracellular membranes.  
As observed before in cholesterol loaded U373 cells, we found only slightly increased stiffness of 
the plasma membrane as measured by TIRFM. However, using EPI-illumination of whole cells, we 
found highly increased membrane stiffness at intracellular membranes in CHO-NPC1−/− cells 
compared to CHO-WT (Figure 2). This is most likely due to the massive cholesterol load of 
intracellular compartments in NPC1−/− cells (Figure 1). These results are in line with our earlier 
measurements of U373 cells, where cholesterol loading increased membrane stiffness and also 
occurred mainly at intracellular compartments, but not at the plasma membrane [33]. 
Figure 2. CHO-NPC1−/− cells show significantly increased membrane stiffness. (A) from 
right to left: generalized polarization (GP) values (with a color code from blue to red 
corresponding to fluid-stiff), corresponding fluorescence intensities (recorded at λ ≥ 420 nm) 
and phase contrast images of CHO-WT and CHO-NPC1−/− cells, incubated with laurdan as 
a function of intracellular cholesterol amount for whole cells (EPI-illumination) and 
plasma membranes (TIRF illumination) at T = 24 °C; (B) GP at the plasma membranes of 
CHO-NPC1−/− cells (TIRF) is only slightly increased compared to CHO-WT cells (n = 32; 
*** p < 0.001). In contrast, GP is strongly increased at intracellular compartments of  
CHO-NPC1−/− cells compared to CHO-WT (EPI) (n = 32; *** p < 0.001). 
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2.3. APP and BACE1 Proximity is Decreased in NPC1−/− Cells, but Not at the Cell Surface. 
To address the question whether APP and BACE1 proximity is altered at the cell surface or at 
intracellular membranes due to an increased cholesterol level in CHO-NPC1−/− cells, we combined 
EPI or TIRF microscopy with fluorescence lifetime measurements, as described earlier [33]. Following 
excitation by picosecond laser pulses, fluorescence decrease of the donor BACE1-GFP was  
mono-exponential with the lifetimes depicted in Figure 3. 
Non-radiative energy transfer from a donor to an acceptor molecule, according to the Förster 
mechanism [47], is often determined from fluorescence lifetime experiments, since the lifetime τ of an 
excited molecular state corresponds to the reciprocal of the sum of its deactivation rates, including 
fluorescence (kF), internal conversion (kIC), intersystem crossing (kISC) and intermolecular energy 
transfer (kET). If τ is the lifetime of a donor molecule in presence of, and τ0 in absence of an acceptor 
molecule, the difference 1/τ−1/τ0 reflects the energy transfer rate kET from the donor to the acceptor. 
For dipole-dipole interaction, this rate is proportional to R−6, with R representing the intermolecular 
distance, which generally is smaller than about 10 nm. An increase of the fluorescence lifetime τ of the 
donor can be related to a decrease of kET, and therefore, to a decrease of donor-acceptor (in this case 
BACE1-GFP and APP-mRFP) proximity.  
Figure 3. Fluorescence lifetime of GFP for probing GFP-RFP proximity in BACE1-GFP 
and APP-mRFP double stably transfected CHO cells. Lifetimes at plasma membranes, as 
shown by TIRF, are not significantly altered. Under EPI-illumination, BACE1-GFP 
lifetimes of CHO-NPC1−/− cells are significantly higher compared to CHO-WT cells 
(Mann-Whitney rank sum test: * p = 0.039). 
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In agreement with previous results [33] (and in contrast to an APP-BACE positive control [33]), we 
found no significant changes in donor lifetime and, therefore, in APP-BACE1 proximity at the cell 
surface as measured by TIRFM. However, under EPI illumination, we observed a significant increase 
of donor lifetime in CHO-NPC1−/− cells compared to CHO-WT (Figure 3). This indicates that APP 
and BACE1 come less often into close proximity in CHO-NPC1−/− cells compared to CHO-WT and 
that that enhanced membrane stiffness due to cholesterol enrichment is associated with decreased 
proximity of APP and BACE1 in CHO-NPC1−/− cells.  
Data on how cholesterol influences APP processing are quite inconsistent. Age of the cells, as well 
as cell lines used for the experiments, seem to influence the results. However, consistent with our 
previous findings, most data from in vitro and in vivo experiments show increased APP β-cleavage 
upon cholesterol increase, and reduced β-cleavage and increased α-cleavage upon cholesterol  
depletion [27,34,44,48–51]. To understand how BACE1-cleavage of APP is increased, while at the 
same time APP-BACE1 proximity is reduced, seems to be quite challenging. But one has to keep in 
mind that, besides its influence on cellular membranes, altered cholesterol levels induce complex 
alterations in cell metabolism and might influence different membranes to different extent. It is 
possible that, in some compartments, APP-BACE1 proximity is decreased, whereas in others, APP 
processing by BACE1 is increased. Although in CHO-NPC1−/− cells APP and BACE1 were shown to 
accumulate in the same compartments (transferrin receptor-positive vesicles) [52], their routing to and 
out of these compartments could be quite different, which in turn could result in their overall decreased 
proximity within the cell. Indeed, we showed recently a strong colocalization of APP, and not BACE1, 
with early endosomal marker EEA1, and a marked accumulation of APP C-terminal fragments  
(APP-CTFs), and not BACE1, within late endosomes in CHO-NPC1−/− cells [52]. Regarding transport 
and endocytosis rates and mechanisms, there is little data about alterations upon cholesterol 
enrichment, but it might lead to accelerated turnover and endocytosis of APP and BACE1 in lipid  
rafts [53], thereby promoting APP processing by BACE1. We have previously reported that APP 
localization is shifted to lipid rafts in CHO-NPC1−/− cells [54]. Another explanation might be the 
direct impact of cholesterol environment on BACE1 activity. In living cells, BACE1 seems to require 
intact rafts for activity [23], and BACE1 outside rafts seems to be inactive. Cholesterol enrichment, as 
found in CHO-NPC1−/−, might change raft composition and size, thereby altering BACE1 activity. 
Additionally, FRET efficiency is strongly dependent on the spatial orientation of donor and acceptor 
molecules and, in particular, orientation of donor and acceptor dipole moments. Besides cholesterol, 
lipid rafts are also enriched in large molecules, like sphingolipids, and proteins that project beyond the 
phospholipid bilayer and might influence the spatial orientation of the donor and acceptor molecules. 
Therefore, we cannot completely rule out that increased membrane stiffness and altered raft 
composition due to cholesterol enrichment might promote APP-BACE1 interaction, but at the same 
time, influence GFP-RFP FRET efficiency due to sterical hindrance.  
3. Experimental Section  
3.1. Expression Constructs  
We utilized previously described APP695-rfp and BACE1-gfp expression constructs [55–57].  
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3.2. Cell Culture and Stable Transfection  
Chinese hamster ovary wild type (CHO-WT) cells and CHO-NPC1−/− cells (kindly provided by Dr. 
Daniel Ory) were maintained as described previously [52]. Cell lines stably expressing APP-mRFP 
and BACE1-GFP were established by co-transfection using Lipofectamine LTX (Invitrogen, 
Darmstadt, Germany) and selection in the media supplemented with an appropriate selective antibiotic. 
Both cell lines were seeded on microscope slides and maintained in DMEM (Gibco) supplemented 
with 10% fetal bovine serum (FBS) and 1x penicillin/streptomycin (P/S). Cells were incubated in 5% 
CO2 and 37 °C for 24 h to 36 h before analysis.  
3.3. Cholesterol Quantification  
CHO-WT and CHO-NPC1−/− cells were plated in 6-well plates and grown for 48 h in 10% FBS 
DMEM/F12 medium until confluent. Cells from each well were collected and lysed in CoIP lysis 
buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 2 mM EDTA, 1% NP40) containing protease inhibitor 
cocktail (Roche Applied Science). Protein concentration in cell lysates (mg protein/mL) was 
determined with the DC Protein Assay (BioRad). The protein concentration in cell lysate is 
proportional to the number of cells collected for lysis. Concentration of free cholesterol, cholesterol 
esters and total cholesterol in cell lysates (µg cholesterol/mL) was measured using Amplex Red 
Cholesterol Assay Kit (Molecular Probes), following the manufacturer’s instructions. Cholesterol 
concentration was normalized according to protein concentration of the matching sample. Thus, 
cholesterol levels were expressed in µg cholesterol/mg protein. 
3.4. Filipin Staining  
Filipin (Sigma Aldrich) staining was done as previously described [58]. The cells were mounted 
and were viewed by fluorescence microscope (Olympus BX51). 
3.5. Laurdan Staining and GP Measurements  
The hydrophobic membrane marker 6-dodecanoyl-2-dimethylamino naphthalene (laurdan) was 
obtained from Molecular Probes (Göttingen, Germany) and prepared as a 2 mM stock solution in 
ethanol. For GP measurement, cells were grown on microscope object slides for 48 h prior to rinsing 
with Earl’s balanced salt solution (EBSS) and incubation with laurdan (8 µM in culture medium) for 
60 min at 37 °C. GP measurement and calculation was performed as described previously [45] using 
the following equation: GP = (I440 − I490)/(I440 + I490), with I440 and I490 representing the fluorescence 
intensities measured at 440 nm and 490 nm, respectively. 
3.6. Microscopic Imaging and FRET Analysis  
Microscopic experiments were performed with a picosecond laser diode emitting light at 470 nm 
(LDH 470 with driver PDL 800 B, Picoquant, Berlin, Germany; average power 1 mW, pulse duration 
70 ps, repetition rate 40 MHz) as the excitation source of GFP. This laser diode was adapted to a 
fluorescence microscope (Axioplan 1, Carl Zeiss Jena, Germany) with either a multimode fiber and a 
dichroic mirror (reflecting light at wavelengths λ ≤ 510 nm) for EPI-illumination, or with a single 
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mode fiber (Point Source, kineFlex, Southampton, UK) for illumination by an evanescent 
electromagnetic field (penetration depth around 130 nm) with a specific device for total internal 
reflection (TIR) fluorescence microscopy [59]. In the first case, whole cells were illuminated, whereas 
in the second case, selective illumination of the plasma membranes and adjacent cellular sites 
occurred. Using a purpose-made optical setup [33,45,60], one could easily switch between the two 
excitation modes. For measuring fluorescence decay kinetics of single cells, a long pass filter 
transmitting light above 515 nm and a time-gated image-intensifying CCD camera system (Picostar 
HR 12; LaVision, Göttingen, Germany) with a time resolution of 200 ps were used, as described in 
detail elsewhere [61]. Fluorescence decay kinetics of individual cells were recorded by shifting the 
time gate of 200 ps over an axis of 20 ns. Since the fluorescence intensity of mRFP was very low, all 
fluorescence was related to GFP. 
For GP evaluation, cells incubated with laurdan (see above) were used and exposed to a laser diode 
emitting light at 391 nm (LDH 400 with driver PDL 800 B; Picoquant, Berlin) upon EPI-illumination and a 
laser diode at 375 nm (LDH 375; Picoquant, Berlin) upon TIR illumination. Simultaneous use of both laser 
diodes facilitated parallel measurements under maintenance of similar extinction coefficients [46]. 
Fluorescence spectra of single cells were recorded at λ ≥ 420 nm with a polychromator and an image 
intensifying detection unit (IMD 4562, Hamamatsu Photonics, Ichino-Cho, Japan) [62] fixed on top of 
the microscope. In addition, fluorescence images were recorded at 450 ± 20 nm and 490 ± 20 nm using 
appropriate interference filters and an electron multiplying (EM-)CCD camera (DV887DC, ANDOR 
Technology, Belfast, U.K.) with Peltier cooling and a sensitivity below 10-16 W/pixel. 
4. Conclusion  
Combination of FRET and TIRF (TIRET) (in comparison with FRET under EPI illumination) is an 
appropriate and very selective technique to examine molecular interactions in the plasma membrane of 
living cells, since illumination by an evanescent electromagnetic field arising at a cell-substrate surface 
is limited to less than 100 nm. By combining FRET with EPI illumination, we were able to confirm 
previously observed cholesterol-associated alterations in proximity of AD relevant proteins APP and 
BACE1 at intracellular compartments, in contrast to the plasma membranes. In the future, alterations 
in protein proximity may be further localized within the cells by fluorescence lifetime imaging 
microscopy (FLIM), where the same experimental setup can be used. This may permit more detailed 
information about processes involved in the formation of neurodegenerative disorders and other diseases.  
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